{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T20:27:34Z","timestamp":1789936054205,"version":"4.0.1"},"reference-count":43,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2018,4,13]],"date-time":"2018-04-13T00:00:00Z","timestamp":1523577600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008656","name":"Fondation Innovations en Infectiologie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008656","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2018.00704","type":"journal-article","created":{"date-parts":[[2018,4,13]],"date-time":"2018-04-13T00:15:41Z","timestamp":1523578541000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":19,"title":["One-Year Follow-Up of Natural Killer Cell Activity in Multiple Myeloma Patients Treated With Adjuvant Lenalidomide Therapy"],"prefix":"10.3389","volume":"9","author":[{"given":"Laurie","family":"Besson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Charrier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lionel","family":"Karlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omran","family":"Allatif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Mar\u00e7ais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Rouzaire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucie","family":"Belmont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Attal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Lombard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Salles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Walzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9bastien","family":"Viel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2018,4,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1038\/nature09837","article-title":"Initial genome sequencing and analysis of multiple myeloma","volume":"471","author":"Chapman","year":"2011","journal-title":"Nature"},{"key":"B2","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1517\/14728210802676278","article-title":"Emerging therapies for multiple myeloma","volume":"14","author":"Podar","year":"2009","journal-title":"Expert Opin Emerg Drugs"},{"key":"B3","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/ni1582","article-title":"Functions of natural killer cells","volume":"9","author":"Vivier","year":"2008","journal-title":"Nat Immunol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/sj.emboj.7600019","article-title":"Unravelling natural killer cell function: triggering and inhibitory human NK receptors","volume":"23","author":"Moretta","year":"2003","journal-title":"EMBO J"},{"key":"B5","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/82_2010_86","article-title":"Fc\u03b3Rs in health and disease","volume":"350","author":"Nimmerjahn","year":"2011","journal-title":"Curr Top Microbiol Immunol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1182\/blood-2004-04-1422","article-title":"HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells","volume":"105","author":"Carbone","year":"2005","journal-title":"Blood"},{"key":"B7","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1158\/0008-5472.CAN-06-4230","article-title":"The requirement for DNAM-1, NKG2D, and NKp46 in the natural killer cell-mediated killing of myeloma cells","volume":"67","author":"El-Sherbiny","year":"2007","journal-title":"Cancer Res"},{"key":"B8","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1172\/JCI77181","article-title":"Immunosurveillance and therapy of multiple myeloma are CD226 dependent","volume":"125","author":"Guillerey","year":"2015","journal-title":"J Clin Invest"},{"key":"B9","doi-asserted-by":"publisher","first-page":"e26011","DOI":"10.4161\/onci.26011","article-title":"Monitoring NK cell activity in patients with hematological malignancies","volume":"2","author":"Viel","year":"2013","journal-title":"Oncoimmunology"},{"key":"B10","doi-asserted-by":"publisher","first-page":"4771","DOI":"10.1182\/blood-2011-05-356063","article-title":"Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide","volume":"118","author":"Zhu","year":"2011","journal-title":"Blood"},{"key":"B11","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1053\/j.seminhematol.2005.10.001","article-title":"Lenalidomide and thalidomide: mechanisms of action \u2013 similarities and differences","volume":"42","author":"Anderson","year":"2005","journal-title":"Semin Hematol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1182\/blood.V98.1.210","article-title":"Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma","volume":"98","author":"Davies","year":"2001","journal-title":"Blood"},{"key":"B13","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1111\/j.1365-2141.2004.05286.x","article-title":"Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application","volume":"128","author":"Hayashi","year":"2005","journal-title":"Br J Haematol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1111\/bjh.12708","article-title":"Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.)","volume":"164","author":"Gandhi","year":"2014","journal-title":"Br J Haematol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"23609","DOI":"10.18632\/oncotarget.4603","article-title":"The IMiDs targets IKZF-1\/3 and IRF4 as novel negative regulators of NK cell-activating ligands expression in multiple myeloma","volume":"6","author":"Fionda","year":"2015","journal-title":"Oncotarget"},{"key":"B16","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1182\/blood-2015-01-625004","article-title":"Lenalidomide augments actin remodeling and lowers NK-cell activation thresholds","volume":"126","author":"Lagrue","year":"2015","journal-title":"Blood"},{"key":"B17","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1038\/leu.2009.279","article-title":"Testing the NKT cell hypothesis in lenalidomide-treated myelodysplastic syndrome patients","volume":"24","author":"Chan","year":"2010","journal-title":"Leukemia"},{"key":"B18","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/bmt.2009.155","article-title":"Lenalidomide as salvage therapy after allo-SCT for multiple myeloma is effective and leads to an increase of activated NK (NKp44(+)) and T (HLA-DR(+)) cells","volume":"45","author":"Lioznov","year":"2010","journal-title":"Bone Marrow Transplant"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","article-title":"Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma","volume":"376","author":"Attal","year":"2017","journal-title":"N Engl J Med"},{"key":"B20","volume-title":"R: A Language and Environment for Statistical Computing","year":"2015"},{"key":"B21","doi-asserted-by":"publisher","first-page":"2712","DOI":"10.1200\/JCO.2013.54.8164","article-title":"Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone du My\u00e9lome","volume":"32","author":"Roussel","year":"2014","journal-title":"J Clin Oncol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"3853","DOI":"10.1182\/blood-2010-04-281675","article-title":"Expression patterns of NKG2A, KIR, and CD57 define a process of CD56dim NK-cell differentiation uncoupled from NK-cell education","volume":"116","author":"Bj\u00f6rkstr\u00f6m","year":"2010","journal-title":"Blood"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1084\/jem.20090681","article-title":"The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans","volume":"206","author":"Brandt","year":"2009","journal-title":"J Exp Med"},{"key":"B24","doi-asserted-by":"publisher","first-page":"3664","DOI":"10.1182\/blood-2004-05-2058","article-title":"Imprint of human cytomegalovirus infection on the NK cell receptor repertoire","volume":"104","author":"Gum\u00e1","year":"2004","journal-title":"Blood"},{"key":"B25","doi-asserted-by":"publisher","first-page":"144","DOI":"10.3389\/fimmu.2016.00144","article-title":"Functional reconstitution of natural killer cells in allogeneic hematopoietic stem cell transplantation","volume":"7","author":"Ullah","year":"2016","journal-title":"Front Immunol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1073\/pnas.0609692104","article-title":"Identification, activation, and selective in vivo ablation of mouse NK cells via NKp46","volume":"104","author":"Walzer","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B27","doi-asserted-by":"publisher","first-page":"5984","DOI":"10.1158\/1078-0432.CCR-05-0577","article-title":"Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model","volume":"11","author":"Hernandez-Ilizaliturri","year":"2005","journal-title":"Clin Cancer Res"},{"key":"B28","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1111\/j.1365-2141.2007.06841.x","article-title":"Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo","volume":"140","author":"Reddy","year":"2008","journal-title":"Br J Haematol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1097\/CJI.0000000000000097","article-title":"Lenalidomide synergistically enhances the effect of dendritic cell vaccination in a model of murine multiple myeloma","volume":"38","author":"Nguyen-Pham","year":"2015","journal-title":"J Immunother"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1056\/NEJMoa1114138","article-title":"Lenalidomide maintenance after stem-cell transplantation for multiple myeloma","volume":"366","author":"Attal","year":"2012","journal-title":"N Engl J Med"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1056\/NEJMoa1114083","article-title":"Lenalidomide after stem-cell transplantation for multiple myeloma","volume":"366","author":"McCarthy","year":"2012","journal-title":"N Engl J Med"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1182\/blood-2010-04-278432","article-title":"The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy","volume":"117","author":"Hsu","year":"2011","journal-title":"Blood"},{"key":"B33","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1158\/1078-0432.CCR-15-1419","article-title":"The IL-15-based ALT-803 complex enhances Fc\u03b3RIIIa-triggered NK cell responses and in vivo clearance of B cell lymphomas","volume":"22","author":"Rosario","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B34","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1002\/ijc.29686","article-title":"Therapeutic administration of IL-15 superagonist complex ALT-803 leads to long-term survival and durable antitumor immune response in a murine glioblastoma model","volume":"138","author":"Mathios","year":"2016","journal-title":"Int J Cancer"},{"key":"B35","doi-asserted-by":"publisher","first-page":"4781","DOI":"10.1172\/JCI74337","article-title":"Cytokine therapy reverses NK cell anergy in MHC-deficient tumors","volume":"124","author":"Ardolino","year":"2014","journal-title":"J Clin Invest"},{"key":"B36","doi-asserted-by":"publisher","first-page":"4042","DOI":"10.1172\/JCI90387","article-title":"CD56bright NK cells exhibit potent antitumor responses following IL-15 priming","volume":"127","author":"Wagner","year":"2017","journal-title":"J Clin Invest"},{"key":"B37","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/ni.2936","article-title":"The metabolic checkpoint kinase mTOR is essential for IL-15 signaling during the development and activation of NK cells","volume":"15","author":"Mar\u00e7ais","year":"2014","journal-title":"Nat Immunol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1158\/2326-6066.CIR-17-0279","article-title":"IL15 infusion of cancer patients expands the subpopulation of cytotoxic CD56bright NK cells and increases NK-cell cytokine release capabilities","volume":"5","author":"Dubois","year":"2017","journal-title":"Cancer Immunol Res"},{"key":"B39","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1200\/JCO.2014.57.3329","article-title":"Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer","volume":"33","author":"Conlon","year":"2015","journal-title":"J Clin Oncol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"e1008814","DOI":"10.1080\/2162402X.2015.1008814","article-title":"Trial watch: immunomodulatory monoclonal antibodies for oncological indications","volume":"4","author":"Buqu\u00e9","year":"2015","journal-title":"Oncoimmunology"},{"key":"B41","doi-asserted-by":"publisher","first-page":"4324","DOI":"10.1182\/blood-2012-06-438028","article-title":"A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed\/refractory multiple myeloma","volume":"120","author":"Benson","year":"2012","journal-title":"Blood"},{"key":"B42","doi-asserted-by":"publisher","first-page":"6387","DOI":"10.1182\/blood-2011-06-360255","article-title":"IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect","volume":"118","author":"Benson","year":"2011","journal-title":"Blood"},{"key":"B43","unstructured":"VielS\n          R\u00e9gulation des cellules NK par le TGF-\u03b2. Immunologie2016"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fimmu.2018.00704\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,4,13]],"date-time":"2018-04-13T00:15:46Z","timestamp":1523578546000},"score":1,"resource":{"primary":{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fimmu.2018.00704\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,13]]},"references-count":43,"alternative-id":["10.3389\/fimmu.2018.00704"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2018.00704","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,13]]},"article-number":"704"}}